C. Koller

发表

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

M. Andreeff, H. Kantarjian, J. Cortes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

B. Davidson, P. Daddona, B. Mitchell, 1983, The Journal of clinical investigation.

valproic acid in patients with leukemia -deoxycytidine with ' Phase 1/2 study of the combination of 5-aza-2

G. Rosner, E. Estey, Z. Estrov, 2013 .

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.

E. Estey, H. Kantarjian, W. Plunkett, 1993, Blood.

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

E. Estey, M. Andreeff, H. Kantarjian, 2003, Cancer.

T-cell prolymphocytic leukemia: a single-institution experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005, Clinical lymphoma & myeloma.

Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia

H. Kantarjian, W. Plunkett, M. Keating, 2002, Leukemia & lymphoma.

Treatment of AML and High Risk MDS at M.D. Anderson: The Lone Star Approach

E. Estey, J. Cortes, F. Giles, 2003 .

Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia

H. Kantarjian, J. Cortes, S. Pierce, 2004, Cancer.

ATP depletion as a consequence of adenosine deaminase inhibition in man.

J. Hutton, B. Mitchell, M. S. Coleman, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo.

B. Mitchell, R. Heyn, C. Koller, 1980, Blood.

leukemia and other hematologic malignancies Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid

R. Kurzrock, G. Garcia-Manero, M. Talpaz, 2013 .

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.

H. Kantarjian, J. Cortes, C. Koller, 2002, Leukemia research.

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010, Cancer.

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib

G. Daley, H. Kantarjian, J. Cortes, 2007, Cancer.

Pregnancy among patients with chronic myeloid leukemia treated with imatinib.

H. Kantarjian, J. Cortes, M. Talpaz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

M. Andreeff, H. Kantarjian, M. Talpaz, 1995, Blood.

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

H. Kantarjian, J. Cortes, S. Verstovsek, 2004, Blood.

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

B. Barlogie, H. Kantarjian, W. Velasquez, 1989, Blood.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

H. Kantarjian, F. Ravandi, S. Pierce, 2011, Blood.

Central nervous system relapse in adults with acute lymphoblastic leukemia

H. Kantarjian, J. Cortes, S. O'brien, 2002, Cancer.

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.

Z. Estrov, R. Kurzrock, T. Manshouri, 2002, Blood.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Z. Estrov, R. Kurzrock, T. Manshouri, 2002 .

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.

E. Estey, M. Andreeff, H. Kantarjian, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influenza among hospitalized adults with leukemia.

R. Couch, L. Elting, J. Englund, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Using Human Observations to Gain Biologic Insights and New Treatments; Discovery of a Quadruplex-Forming DNA Aptamer as an Anticancer Agent

David E. Muench, Donald M Miller, C. Koller, 2012 .

In vivo differentiation of blast-phase chronic granulocytic leukemia. Expression of c-myc and c-abl protooncogenes.

C. Koller, D. Miller, V. Campbell, 1985, The Journal of clinical investigation.

Topotecan a nd C ytarabine I s a n A ctive C ombination Regimen i n M yelodysplastic S yndromes a nd C hronic Myelomonocytic L eukemia

E. Estey, M. Andreeff, H. Kantarjian, 1999 .

FLAG-Ida, an Effective Regimen for High Risk AML

M. Andreeff, S. Kornblau, E. Freireich, 1998 .

An assay of deoxyadenosine and adenosine in human plasma by HPLC.

B. Mitchell, P. Stetson, L. Nichamin, 1980, Biochemical medicine.

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004, Clinical Cancer Research.

The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

E. Estey, H. Kantarjian, J. Cortes, 2008, Clinical Cancer Research.

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Leukemia research.

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction

Yu Shen, H. Kantarjian, M. Munsell, 2003, Cancer.

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Supportive Care in Cancer.

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2004 .

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

S. Pileri, M. Baccarani, P. Zinzani, 2005, Haematologica.

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.

H. Kantarjian, J. Cortes, M. Keating, 2004 .

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

H. Kantarjian, J. Cortes, M. Keating, 2003, Cancer.

A Phase I trial of weekly lomustine in patients with advanced cancer

R. Benjamin, S. Legha, C. Koller, 1994, Cancer.

Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.

Z. Estrov, D. Harris, R. Kurzrock, 1996, Leukemia.

myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute

Z. Estrov, J. Cortes, S. Verstovsek, 2013 .

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

H. Kantarjian, M. Keating, S. O'brien, 2011, Blood.

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

Z. Estrov, R. Kurzrock, E. Freireich, 2006, Leukemia & lymphoma.

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

E. Estey, H. Kantarjian, W. Plunkett, 1992, Leukemia.

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Front. Oncol..

Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2012, British journal of haematology.

The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia

H. Kantarjian, J. Cox, C. Koller, 2004, Cancer.

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

M. Andreeff, M. Sznol, H. Kantarjian, 2004, Clinical Cancer Research.

Treatment of myelodysplastic syndromes with AML-type chemotherapy

M. Andreeff, H. Kantarjian, S. Pierce, 1993 .

Treatment of Newly-Diagnosed Acute Promyelocytic Leukemia with Liposomal All-Trans Retinoic Acid

E. Estey, H. Kantarjian, J. Cortes, 2001, Leukemia & lymphoma.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Susan O'Brien, Weiqiang Zhao, Gautam Borthakur, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.

E. Estey, H. Kantarjian, S. Kornblau, 1996, Leukemia.

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Cancer.

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

G. Daley, H. Kantarjian, J. Cortes, 2004 .

Molecular analysis of chromosome 22 breakpoints in adult Philadelphia‐positive acute lymphoblastic leukaemia

R. Kurzrock, J. Gutterman, M. Talpaz, 1987, British journal of haematology.

Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.

E. Jabbour, C. Koller, M. Welch, 2011, Clinical lymphoma, myeloma & leukemia.

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

K. Do, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia

E. Estey, S. Sacchi, S. Kornblau, 1997, Leukemia.

Phase II Study of Lenalidomide (CC-5013, Revlimid®) for Patients (pts) with Myelofibrosis (MF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2005 .

Randomized P hase I /II S tudy o f T roxacitabine C ombined W ith Cytarabine, I darubicin, o r T opotecan i n P atients W ith Refractory M yeloid L eukemias

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003 .

Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Z. Estrov, M. Keating, S. O'brien, 2009, Blood.

E. Estey, H. Kantarjian, M. Keating, 1994, Leukemia.

Mithramycin selectively inhibits transcription of G-C containing DNA.

C. Koller, S. Thomas, J. Sanchez, 1987, The American journal of the medical sciences.

S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.

J. Kurtzberg, B. Mitchell, M. Hershfield, 1983, Cancer research.

Simultaneous detection of type A and type B PML/retinoic acid receptor alpha fusion transcripts in acute promyelocytic leukemia.

C. Koller, V. Kohli, 1995, Blood.

Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte‐macrophage colony‐stimulating factor

W. Velasquez, J. Gutterman, M. Keating, 1990, American journal of hematology.

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Kim-Anh Do, Susan O'Brien, Jorge Cortes, 2007, Blood.

Multiple‐dose granulocyte‐macrophage–colony‐stimulating factor plus 23‐valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia

D. Musher, M. Keating, S. O'brien, 2008, Cancer.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Cancer.

Adenosine Deaminase Deficiency with

B. Davidson, P. Daddona, B. Mitchell, 1983 .

Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia.

R. Kurzrock, J. Gutterman, M. Talpaz, 1987 .

Chemotherapy-induced acral erythema: desquamating lesions involving the hands and feet.

S. S. Kroll, C. Koller, S. Dreizen, 1989, Annals of plastic surgery.

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

E. Estey, H. Kantarjian, J. Cortes, 2004, Investigational New Drugs.

Quantitation of the nucleophosmin/B23-translocation using imaging analysis.

Y. Qi, C. Koller, P. Chan, 1996, Cancer letters.

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.

E. Estey, M. Andreeff, H. Kantarjian, 1994, The New England journal of medicine.

Nucleoside analogs in treatment of chronic lymphocytic leukemia.

E. Estey, H. Kantarjian, S. O'brien, 1993, Leukemia & lymphoma.

Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.

E. Estey, H. Kantarjian, W. Plunkett, 1993, Leukemia & lymphoma.

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

H. Kantarjian, E. Freireich, M. Talpaz, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.

H. Kantarjian, M. Keating, S. O'brien, 1991, The American journal of medicine.

A Phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

H. Kantarjian, S. O'brien, E. Feldman, 1999, Cancer.

2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies

E. Estey, R. Kurzrock, H. Kantarjian, 1991 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

H. Kantarjian, S. O'brien, S. Faderl, 2007 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2005 .

Role of radiation therapy to the brain in leukemic patients with cranial nerve palsies in the absence of radiological findings.

J. Cox, C. Koller, C. Ha, 1999, Leukemia & lymphoma.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Z. Cabantchik, P. Greenberg, G. Warsi, 2010, Leukemia research.

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.

E. Estey, H. Kantarjian, J. Cortes, 2005, Blood.

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

M. Andreeff, H. Kantarjian, J. Cortes, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine

J. Cortes, M. Talpaz, M. Keating, 1997, Leukemia.

Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia

J. Cortes, M. Talpaz, M. Albitar, 1997, Leukemia.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

H. Kantarjian, M. Keating, S. O'brien, 2011, Blood.

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007 .

Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)

E. Estey, J. Issa, H. Kantarjian, 2004 .

Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS).

E. Estey, J. Issa, H. Kantarjian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

High‐dose liposomal daunorubicin and high‐dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

E. Estey, Yu Shen, J. Cortes, 2001, Cancer.

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

M. Talpaz, M. Keating, S. Lerner, 1997, Leukemia.

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

P. Thall, E. Estey, H. Kantarjian, 1992, Blood.

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

H. Kantarjian, E. Freireich, M. Keating, 1989, Cancer.

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

E. Estey, H. Kantarjian, S. Kornblau, 1997, Blood.

An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.

E. Estey, L. Elting, G. Bodey, 1993, The Journal of antimicrobial chemotherapy.

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.

E J Freireich, E. Estey, H. Kantarjian, 1998, Blood.

Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

H. Kantarjian, E. Jabbour, A. Taher, 2008, Cancer.

Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo.

B. Mitchell, R. Heyn, C. Koller, 1980, Blood.

Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.

M. Grever, B. Mitchell, C. Koller, 1979, Cancer treatment reports.

Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.

C. Koller, D. Miller, 1986, The New England journal of medicine.

Chronic myelogenous leukemia in nonlymphoid blastic phase

S. Sacchi, H. Kantarjian, J. Cortes, 1999, Cancer.

Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.

C. Koller, S. Thomas, R. Snyder, 1991, The Journal of clinical investigation.

Mithramycin blocks protein binding and function of the SV40 early promoter.

R. Ray, C. Koller, S. Thomas, 1989, The Journal of clinical investigation.

Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.

B. Mitchell, C. Koller, 1983, Cancer research.

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia

H. Kantarjian, J. Cortes, S. O'brien, 2002, Cancer.

untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously

K. Do, H. Kantarjian, G. Garcia-Manero, 2013 .

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.

Z. Estrov, H. Kantarjian, M. Keating, 2006, Blood.

The MD Anderson Manual of Medical Oncology

H. Kantarjian, R. Wolff, C. Koller, 2006 .

Hodgkin transformation of chronic lymphocytic leukemia

H. Kantarjian, A. Tsimberidou, C. Bueso-Ramos, 2006, Cancer.

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

K. Do, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results o f T reatment W ith H yper-CVAD, a D ose-Intensive Regimen, i n A dult A cute L ymphocytic L eukemia

M. Andreeff, H. Kantarjian, J. Cortes, 2000 .

Resul ts of Treatment With Hyper-CVAD , a Dose-Intens ive Regimen , in Adul t Acute Lymphocyt ic Leukemia

M. Andreeff, H. Kantarjian, J. Cortes, 2000 .

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.

M. Andreeff, H. Kantarjian, J. Cortes, 1996, Leukemia & lymphoma.

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

H. Kantarjian, J. Cortes, W. Wierda, 2003, Blood.

Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.

E. Estey, M. Andreeff, W. Benedict, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fludarabine therapy in macroglobulinemic lymphoma.

R. Kurzrock, H. Kantarjian, M. Keating, 1990, Blood.

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

B. Barlogie, H. Kantarjian, W. Plunkett, 1989, Blood.

Detection of leukemic clone maturation in vivo by premature chromosome condensation.

H. Kantarjian, W. Hittelman, B. Andersson, 1988, Blood.

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

E. Estey, M. Andreeff, S. Arbuck, 1996, Blood.

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.

E. Estey, H. Kantarjian, M. Keating, 1993, Blood.

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

B. Cheson, M. Minden, M. Berger, 2008, Clinical Cancer Research.

Response to 2'-deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell leukemia.

D. Longo, K. Foon, C. Koller, 1986, Blood.

Primary refractory and relapsed adult acute lymphoblastic leukemia

Terry L. Smith, J. Cortes, S. Pierce, 1999, Cancer.

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

L. Zwelling, H. Kantarjian, W. Plunkett, 1993 .

myelodysplastic syndrome and chronic myelomonocytic leukemia Topotecan, a topoisomerase I inhibitor, is active in the treatment of

M. Andreeff, S. Arbuck, H. Kantarjian, 2011 .

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

E. Estey, H. Kantarjian, S. Kornblau, 1998, Leukemia & lymphoma.

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Michael Rytting, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

High‐dose chemotherapy in high‐risk myelodysplastic syndrome

E. Estey, J. Cortes, S. O'brien, 2001, Cancer.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

J. Issa, M. Andreeff, H. Kantarjian, 2005 .

syndromes Angiogenesis in acute and chronic leukemias and myelodysplastic

E. Estey, Z. Estrov, H. Kantarjian, 2013 .

Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.

B. Barlogie, H. Kantarjian, T. Manshouri, 2000, Blood.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

H. Kantarjian, J. Cortes, G. Borthakur, 2009, Blood.

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

precursor B-lineage acute lymphoblastic leukemia Prognostic significance of CD 20 expression in adults with de novo

H. Kantarjian, J. Cortes, S. Verstovsek, 2009 .

Prognostic significance of CD 20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

K. Do, H. Kantarjian, G. Garcia-Manero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

J. Issa, M. Andreeff, H. Kantarjian, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

H. Kantarjian, J. Cortes, M. Keating, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of Therapy with Interferon Alpha and Cyclic Combination Chemotherapy in Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Early Chronic Phase

H. Kantarjian, J. Cortes, M. Talpaz, 2001, Leukemia & lymphoma.

Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

B. Cheson, M. Andreeff, H. Kantarjian, 1999, Blood.

Treatment o f P hiladelphia C hromosome-Posit ive E arly Chronic P hase C hronic M yelogenous L eukemia With D aily D oses o f I nterferon A lpha and L ow-Dose C ytarabine

M. Andreeff, H. Kantarjian, J. Cortes, 1999 .

Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.

S. Sacchi, H. Kantarjian, J. Cortes, 1999, Leukemia & lymphoma.

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.

M. Andreeff, H. Kantarjian, J. Cortes, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia

S. Stass, S. O'brien, C. Koller, 1994, Cancer.

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.

E. Estey, H. Kantarjian, M. Talpaz, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL).

H. Kantarjian, T. Manshouri, M. Keating, 2001, Leukemia research.

Combination therapy with arsenic trioxide, all‐trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

Deoxyribonucleoside triphosphate accumulation by leukemic cells.

B. Mitchell, C. Koller, N. Edwards, 1983, Blood.

Eradication of minimal residual disease in hairy cell leukemia.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2006, Blood.

Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL)

S. Verstovsek, S. O'brien, J. Jorgensen, 2005 .

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

E. Estey, R. Kurzrock, H. Kantarjian, 1992, Blood.

2'-Deoxycoformycin toxicity correlates with red cell dATP/ATP ratios

C. Koller, Mitchell, 1981 .

Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

J. Cortes, F. Giles, C. Koller, 2001, Cancer.

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

P. Thall, M. Andreeff, H. Kantarjian, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients

E. Estey, R. Kurzrock, J. Gutterman, 1991, British journal of haematology.

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

E. Estey, Y. Oki, H. Kantarjian, 2006, Blood.

Mitoxantrone and high‐dose etoposide for patients with relapsed or refractory acute leukemia

E. Estey, M. Keating, S. O'brien, 1991, Cancer.

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

H. Kantarjian, F. Ravandi, G. Borthakur, 2009, Leukemia.

CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.

E. Estey, M. Andreeff, H. Kantarjian, 1998, Leukemia & lymphoma.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, T. Kadia, M. Keating, 2009 .

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p.

Z. Estrov, H. Kantarjian, M. Keating, 2008 .

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.

H. Kantarjian, M. Keating, S. Lerner, 1995, Blood.

Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia

M. Andreeff, H. Kantarjian, J. Cortes, 2001 .

Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.

M. Andreeff, S. O'brien, M. Keating, 1995, Leukemia.

Bordetella bronchiseptica pneumonia in a patient with chronic lymphocytic leukemia.

F. Brosius, C. Koller, D. Schaberg, 1987, Southern medical journal.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

M. Andreeff, H. Kantarjian, J. Cortes, 2006 .

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.

L. Zwelling, H. Kantarjian, W. Plunkett, 1993, Blood.

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, S. Verstovsek, F. Ravandi, 2009, Cancer.

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

M. Andreeff, H. Kantarjian, W. Plunkett, 1995, Leukemia.

Change in Liver Iron Concentration (LIC), Serum Ferritin (SF) and Labile Plasma Iron (LPI) Over 1 Year of Deferasirox (DFX/Exjade®) Therapy in a Cohort of Myelodysplastic Patients

P. Greenberg, C. Schiffer, C. Koller, 2008 .

P104 Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade®) therapy in a cohort of patients with MDS

P. Greenberg, C. Schiffer, C. Koller, 2009 .

Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML

E. Estey, H. Kantarjian, M. Keating, 1992 .

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

H. Kantarjian, G. Garcia-Manero, A. Tsimberidou, 2007 .

Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2002, Cancer.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

M. Andreeff, G. Garcia-Manero, J. Cortes, 2005 .

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006 .

Phase I/II study of the combination of 5-azacytidine(5-AC), all-trans retinoic acid (ATRA) and valproic Acid (VPA) in patients with myelodysplastic syndrome (MDS) and leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndrome.

B. Hellerstedt, C. Koller, Xiang Y. Han, 2010, The American journal of the medical sciences.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

H. Kantarjian, J. Cortes, F. Ravandi, 2005 .

Granulocytic sarcoma presenting as pulmonary nodules and lymphadenopathy

E. Orringer, D. Delaney, C. Koller, 1987, Cancer.

The role of point-of-care testing in the early diagnosis of pseudo-hypoxemia in myeloproliferative disorders.

J. Nates, C. Koller, K. Price, 2010, Respiratory care.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Z. Estrov, G. Garcia-Manero, S. Verstovsek, 2007 .

Immune thrombocytopenic purpura.

C. Koller, 1980, The Medical clinics of North America.

Determination of Plicamycin in Plasma by Radioimmunoassay

C. Koller, D. Ho, N. Brown, 1992, Therapeutic drug monitoring.

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2006 .

Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).

H. Kantarjian, S. O'brien, J. Burger, 2010 .

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008 .

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Z. Estrov, T. Manshouri, E. Freireich, 2000 .

Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

E. Estey, Z. Estrov, T. Manshouri, 2000, Leukemia.

A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).

Z. Estrov, M. Andreeff, H. Kantarjian, 2005 .

Plausibility of Delaying Induction Therapy in Untreated AML.

P. Thall, E. Estey, H. Kantarjian, 2004 .

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

E. Estey, Z. Estrov, T. Manshouri, 2000, Blood.

Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2010 .

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

H. Kantarjian, G. Borthakur, E. Jabbour, 2009, Blood.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

H. Kantarjian, J. Cortes, F. Ravandi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

H. Kantarjian, J. Cortes, S. O'brien, 2002, Cancer.

Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever

L. Elting, G. Bodey, W. Velasquez, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Z. Cabantchik, P. Greenberg, G. Warsi, 2010, Leukemia research.

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

K. Do, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I evaluation of semustine in a weekly schedule.

D. Schwalm, R. Wheeler, R. Natale, 1983, Cancer treatment reports.

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

E. Estey, H. Kantarjian, J. Cortes, 2012 .